Institution scientifique

PDX Pharmaceuticals (United States)

Lake Oswego · US · company

78Publications signalées

8335Citations signalées

12Thèmes principaux

Principaux domaines

Cancer Immunotherapy and BiomarkersNanoplatforms for cancer theranosticsImmunotherapy and Immune ResponsesNanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryAdvanced biosensing and bioanalysis techniquesAnimal Behavior and ReproductionWildlife Ecology and ConservationAdvanced Drug Delivery SystemsDrug Solubulity and Delivery SystemsPlant and animal studiesHydraulic Fracturing and Reservoir Analysis

Évolution annuelle

1988 1

1995 2

2000 1

2004 1

2006 1

2007 1

2010 1

2011 2

2013 1

2014 1

2015 7

2016 10

2017 3

2018 4

2019 8

2020 3

2021 6

2022 6

2023 6

2024 3

2025 4

2026 2

Publications récentes

Accès ouvert 2026 preprintOpenAlex

High-Density Wild-Type IL-2 Nanoparticles Preferentially Enhance CD8⁺ T-Cell Expansion and Reprogram the Tumor Microenvironment

Ruijie Wang, Pramod Kumar, Noah A Crumrine, Tongchatra Watcharawittayakul et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 preprintOpenAlex

Patient and Physician Preferences for Treatment in Advanced Renal Cell Carcinoma in Asia-Pacific (PEAR)- A Discrete Choice Experiment

Alison Zhang, Niara Oliveira, Bo Li, Inkeun Park et autres

0 citationsResearch Square

Accès ouvert 2025 articleOpenAlex

PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation

Alison M. Schram, Marc Fellous, Kim LeDuke, Anita Schmid et autres

7 citationsFuture Oncology

Accès ouvert 2025 articleOpenAlex

Levels of the nicotine analog 6-methyl nicotine as a naturally formed tobacco alkaloid in tobacco and tobacco products

James F. Pankow, Wentai Luo, Kevin J. McWhirter, Mohana Sengupta et autres

14 citationsScientific Reports

2025 conference-abstractOpenAlex

Abstract A052: Development of PD-L1 and STING-targeted nanoparticles for lung cancer treatment

Noah Crumrine, Moataz Reda, Pramod Kumar, Ruijie Wang et autres

3 citationsCancer Immunology Research

Accès ouvert 2025 articleOpenAlex

Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy male subjects and elderly healthy male and female subjects

Daniel P. Radin, Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin et autres

8 citationsEuropean Journal of Pharmacology

2024 articleOpenAlex

Introducing: Resource Review

Jill Emery

0 citationsThe Charleston Advisor

Accès ouvert 2024 preprintOpenAlex

Reduction of Neuroinflammation and Seizures in a Mouse Model of CLN1 Batten Disease using the Small Molecule Enzyme Mimetic, N-Tert-Butyl Hydroxylamine

Zach Fyke, Rachel Johansson, Anna I. Scott, Devin Wiley et autres

1 citationbioRxiv (Cold Spring Harbor Laboratory)

2024 conference-abstractOpenAlex

Abstract 4058: Nanoparticle delivery of interleukin-2 induces anti-tumor immune response and therapeutic efficacy in mouse tumor models

Ruijie Wang, Alyssa Wallstrum, Natalie White, Pramod Kumar et autres

0 citationsCancer Research

Accès ouvert 2023 articleOpenAlex

Nanotechnology Applications in Breast Cancer Immunotherapy

Ruijie Wang, Pramod Kumar, Moataz Reda, Alyssa Wallstrum et autres

26 citationsSmall

Accès ouvert 2023 articleOpenAlex

Social opportunities and mate preference improve breeding success in Caribbean iguanas

Jeffrey M. Lemm, Meghan S. Martin‐Wintle

1 citationScientific Reports

2023 conference-abstractOpenAlex

Abstract 3229: Triggering anti-tumor immune response with a nanotherapeutic that targets TLR9 and STAT3 pathways

Worapol Ngamcherdtrakul, Moataz Reda, Cole Baker, Noah Crumrine et autres

1 citationCancer Research

Identifiant ROR

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.